traX Antibody

What is TRAX protein and why is it important in research?

TRAX (translin-associated factor X, also known as TSNAX) is a crucial nuclear protein that forms complexes with translin and plays significant roles in multiple cellular processes. It functions as an endonuclease involved in activating the RNA-induced silencing complex (RISC) when complexed with translin (TSN) . TRAX is primarily located in the nucleus, where it interacts with translin, a DNA-binding protein essential for repairing chromosomal translocations . It contains an N-terminal bipartite nuclear localization signal (NLS) and a leucine zipper domain critical for protein-protein interactions .

Research significance includes:

• Role in DNA double-stranded break repair mechanisms

• Involvement in dendritic RNA processing

• Function as a transcriptional regulator of GAP-43

• Potential implications in neurodevelopment and recovery following injury

• Possible role in spermatogenesis

The multifunctional nature of TRAX makes it an important target for researchers studying transcriptional regulation, DNA repair, and RNA processing mechanisms.

Antibody validation is critical for research reproducibility. To properly validate a TRAX antibody for your specific research:

• Target binding verification: Confirm the antibody binds to TRAX protein using recombinant protein or overexpression systems .

• Complex mixture binding: Verify binding to TRAX in biological samples (cell lysates or tissue sections) where the protein exists in a complex environment .

• Specificity assessment: Conduct knockout/knockdown controls or use multiple antibodies targeting different epitopes of TRAX to confirm specificity .

• Application-specific validation: Test the antibody under the exact experimental conditions you'll use in your research protocol .

• Cross-reactivity testing: If working with multiple species, verify reactivity in each target species separately .

Documentation should include images of all validation experiments with appropriate controls, information about the exact protocols used, and lot-specific data if available. Remember that antibody characterization is a continuous process, not a one-time verification .

What is the difference between monoclonal and polyclonal TRAX antibodies?

For critical research requiring epitope-specific detection, monoclonal antibodies provide advantages. For applications where sensitivity is paramount or where protein confirmation under denaturing conditions is needed, polyclonal antibodies may perform better. Recombinant monoclonal antibodies like EPR13929(B) combine the specificity of monoclonals with improved consistency .

How can I optimize TRAX antibody use for co-immunoprecipitation studies?

Co-immunoprecipitation (Co-IP) experiments with TRAX antibodies require careful optimization to maintain protein-protein interactions while achieving specific pulldown. Based on published protocols:

• Buffer optimization: Use mild lysis buffers (e.g., 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% Triton X-100) with protease inhibitors to preserve native protein interactions .

• Antibody selection: Choose antibodies validated for IP applications, such as EPR13929(B) which has been successfully used at 1:60 dilution for TRAX IP from human testis lysate .

• Pre-clearing step: Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Antibody coupling: Consider covalently coupling the TRAX antibody to beads to eliminate heavy chain interference in western blot detection of co-immunoprecipitated proteins.

• Negative controls: Always include IgG isotype controls and, when possible, TRAX-depleted samples as negative controls.

• Crosslinking consideration: For transient or weak interactions, mild crosslinking (0.5-1% formaldehyde) before lysis may help preserve complexes.

For detecting TRAX interaction with translin or C1D protein, which are documented interacting partners, additional validation using reversed Co-IP (immunoprecipitating with translin antibody and blotting for TRAX) is recommended to confirm specificity of the interaction .

What are common troubleshooting issues with TRAX antibodies in Western blotting?

When optimizing Western blots for TRAX detection, validated antibody dilutions range from 1:500 to 1:20,000 depending on the specific antibody clone and sample type. For human samples, testis lysates have shown consistent detection with multiple antibodies .

How does TRAX antibody perform in immunofluorescence applications for subcellular localization studies?

TRAX protein demonstrates distinctive subcellular localization patterns that can be effectively visualized using immunofluorescence with appropriate TRAX antibodies. For optimal results:

• Fixation method: Acetone fixation at -20°C has been successfully used with EPR13929(B) clone for TRAX detection in HeLa cells .

• Antibody dilution: A 1:100 dilution is typically optimal for immunofluorescence applications with validated TRAX antibodies .

• Expected localization pattern: TRAX demonstrates primarily nuclear localization, consistent with its nuclear functions in DNA repair and transcriptional regulation .

• Counterstaining: DAPI nuclear counterstaining helps confirm nuclear localization versus cytoplasmic distribution .

• Controls: Include negative controls (primary antibody omission) and positive controls (cell lines with known TRAX expression) in each experiment.

For advanced co-localization studies, TRAX antibodies can be paired with antibodies against known interacting partners such as translin or C1D proteins. When performing such experiments, careful selection of primary antibodies from different host species and appropriate fluorophore-conjugated secondary antibodies is essential to avoid cross-reactivity .

What considerations should be made when using TRAX antibodies in tissue immunohistochemistry?

When employing TRAX antibodies for tissue immunohistochemistry, several factors influence experimental success:

• Antigen retrieval: Heat-induced epitope retrieval (HIER) at pH 6 is recommended for TRAX detection in paraffin-embedded tissues .

• Tissue-specific expression: TRAX shows strong cytoplasmic positivity in seminiferous duct cells of human testis, providing an excellent positive control tissue .

• Antibody selection: Polyclonal antibodies like NBP1-80666 have been validated for IHC-P at 1:50-1:200 dilutions .

• Detection system: Polymer-based detection systems typically provide better signal-to-noise ratios than biotin-avidin systems for TRAX detection.

• Background reduction: For tissues with high endogenous peroxidase activity, extended blocking steps (3% H₂O₂, 10-15 minutes) may be necessary.

• Specificity controls: Include tissues from TRAX-knockout models or peptide competition controls to verify antibody specificity.

For multiplexed IHC studies investigating TRAX in relation to other proteins in the same pathway, sequential antibody stripping and reprobing or spectral unmixing technologies can be employed, but these require extensive validation to ensure that the first round of detection does not interfere with subsequent rounds .

How does TRAX function in RNA silencing pathways?

TRAX forms a functional complex with translin (TSN) that acts as an endonuclease involved in activating the RNA-induced silencing complex (RISC) . This complex plays a critical role in small RNA processing pathways. Key aspects of this function include:

• Biochemical activity: The TRAX-TSN complex (also called C3PO - Component 3 Promoter of RISC) possesses endoribonuclease activity that removes the passenger strand from small RNA duplexes.

• Structural requirements: TRAX contains domains essential for its nuclease activity that are distinct from those in translin, creating a composite active site when the two proteins interact.

• Regulatory mechanisms: The endonuclease activity of the TRAX-TSN complex is regulated by interaction with other proteins and possibly by post-translational modifications.

To study TRAX involvement in RNA silencing using antibodies, researchers can:

• Perform TRAX immunoprecipitation followed by RNA sequencing to identify associated small RNAs

• Use TRAX antibodies in chromatin immunoprecipitation to study its association with chromatin during transcriptional silencing

• Employ immunofluorescence to visualize TRAX co-localization with other RISC components like Argonaute proteins

Research in this area has significant implications for understanding post-transcriptional gene regulation and developing RNA-based therapeutics .

What is known about TRAX involvement in DNA damage response?

TRAX plays an important role in cellular response to DNA damage, particularly in DNA double-stranded break (DSB) repair. Key research findings include:

• Nuclear localization: TRAX contains an N-terminal bipartite nuclear localization signal (NLS) that facilitates its transport to the nucleus, where DNA repair occurs .

• Protein interactions: When in complex with translin, TRAX can interact with protein kinase activator C1D, enhancing the complex's ability to participate in DNA repair mechanisms .

• Recruitment function: TRAX facilitates recruitment of other proteins involved in DSB repair processes .

• Research methods: To study TRAX in DNA damage response:

  • Immunofluorescence with TRAX antibodies can track its localization to sites of DNA damage

  • Co-immunoprecipitation can identify dynamic interaction partners following DNA damage induction

  • Chromatin immunoprecipitation can determine TRAX association with damaged chromatin regions

• Experimental approach: Researchers typically induce DNA damage using agents like ionizing radiation, etoposide, or neocarzinostatin, then monitor TRAX localization and interaction dynamics using antibody-based techniques.

Understanding TRAX function in DNA repair has implications for cancer research, as defects in DNA repair pathways contribute to genomic instability and malignant transformation .

How can TRAX antibodies be used to study neurodevelopmental processes?

TRAX has emerging significance in neurodevelopment and neuronal function, with evidence suggesting roles in axonal regeneration and cell proliferation through its regulation of GAP-43 . TRAX antibodies provide valuable tools for investigating these processes:

• Developmental expression profiling: Immunohistochemistry with TRAX antibodies can map expression patterns across different brain regions during development.

• Dendritic RNA processing: TRAX is involved in dendritic RNA processing , which can be studied through:

  • Co-immunoprecipitation of TRAX-associated RNA in neuronal cells

  • Immunofluorescence to track TRAX localization in dendrites

  • Proximity ligation assays to detect interactions with RNA-binding proteins

• Axonal regeneration models: In injury models, TRAX antibodies can monitor changes in expression and localization during recovery phases.

• Methodological considerations:

  • For brain tissue immunohistochemistry, optimize fixation protocols (4% PFA is typical)

  • When working with primary neurons, gentle permeabilization (0.1% Triton X-100) helps preserve delicate structures

  • For development studies, standardize tissue collection timepoints and processing

• Correlation with function: Combine antibody-based detection with functional assays (neurite outgrowth, electrophysiology) to link TRAX molecular dynamics to cellular outcomes.

This research area has significant implications for understanding neurological disorders and potentially developing therapeutic approaches for neuronal regeneration .

How should I select between different TRAX antibody formats for specific research needs?

TRAX antibodies are available in various formats with distinct characteristics suitable for different research applications:

Selection criteria should include:

• Research application compatibility: Match format to technique requirements

• Sample type: Consider whether preservation additives might affect samples

• Detection system: Consider whether direct or indirect detection is preferable

• Downstream applications: Ensure format compatibility with subsequent analyses

For multiplex studies examining TRAX alongside other proteins, consider antibodies raised in different host species to enable simultaneous detection with species-specific secondary antibodies .

What advanced quantification approaches can be used with TRAX antibodies in research?

For precise quantification of TRAX protein in research samples:

• Absolute quantification using recombinant standards:

  • Create a standard curve using purified recombinant TRAX protein

  • Process standards alongside samples using the same TRAX antibody

  • Calculate absolute concentration based on signal intensity comparison

• Multiplex approaches for pathway analysis:

  • For Western blots: Multiplex fluorescent detection using differently labeled secondary antibodies

  • Quantify TRAX relative to pathway partners (translin, C1D) or downstream targets

  • Normalize to appropriate loading controls based on subcellular fraction

• Image analysis for localization quantification:

  • In immunofluorescence: Measure nuclear vs. cytoplasmic TRAX signal intensity ratio

  • Colocalization analysis with Manders' or Pearson's coefficients for protein interaction studies

  • Track dynamic changes following stimulation using time-series imaging

• Mass spectrometry validation:

  • Immunoprecipitate with TRAX antibody followed by MS analysis

  • Label-free quantification or isotope labeling approaches

  • Identify and quantify post-translational modifications

When reporting quantification results, include details about the specific antibody used, its validation for quantitative applications, the dynamic range of detection, and statistical analysis methods to ensure reproducibility and reliability of findings .

How can I develop a ChIP-seq protocol using TRAX antibodies to study its genomic interactions?

Chromatin Immunoprecipitation sequencing (ChIP-seq) with TRAX antibodies can reveal its genomic binding sites and potential role in transcriptional regulation. A methodological approach includes:

• Antibody selection criteria:

  • Choose antibodies specifically validated for ChIP applications

  • Test multiple antibodies targeting different epitopes of TRAX

  • Verify epitope accessibility in crosslinked chromatin

• Protocol optimization:

  • Crosslinking: Test both formaldehyde (1%, 10 min) for protein-DNA interactions and disuccinimidyl glutarate (DSG, 2mM, 30 min) followed by formaldehyde for protein-protein-DNA complexes

  • Sonication: Optimize to achieve 200-500bp fragments

  • Antibody concentration: Typically 2-5μg per ChIP reaction, but requires titration

  • Washing stringency: Balance between specificity and yield

• Essential controls:

  • Input chromatin (pre-immunoprecipitation)

  • IgG isotype control

  • Positive control: ChIP for histone marks

  • Negative control: Gene desert regions

  • Validation by ChIP-qPCR before sequencing

• Bioinformatic analysis considerations:

  • Peak calling algorithms appropriate for transcription factors

  • Motif discovery to identify potential DNA binding sequences

  • Integration with RNA-seq data to correlate binding with gene expression

  • Pathway analysis of TRAX-bound genes

When investigating TRAX interaction with chromatin, consider its known function as a transcriptional regulator of GAP-43 as a positive control region for protocol validation .

What are the best approaches for detecting TRAX in challenging samples like brain tissue?

Brain tissue presents unique challenges for TRAX detection due to its complex composition and high lipid content. Optimized approaches include:

• Extraction optimization:

  • Use specialized brain tissue lysis buffers containing 1% SDS, 1% Triton X-100, 1% sodium deoxycholate

  • Include phosphatase inhibitors to preserve post-translational modifications

  • Sonicate samples to break down extracellular matrix components

• Fixation considerations for IHC/IF:

  • Short post-fixation (4% PFA, 24-48h) followed by careful washing

  • Extended antigen retrieval (20-30 min) with citrate buffer (pH 6.0)

  • Consider using tyramide signal amplification for low abundance detection

• Region-specific analysis:

  • Microdissection of specific brain regions before processing

  • Compare expression across different neural cell types using co-labeling

  • Consider single-cell approaches for heterogeneous populations

• Antibody selection criteria:

  • For fluorescence applications, select antibodies with minimal brain autofluorescence interference

  • Use antibodies specifically validated in neural tissues

  • Consider directly conjugated primary antibodies to reduce background

• Controls and validation:

  • Include region-matched control tissues

  • Compare multiple antibodies targeting different TRAX epitopes

  • Validate findings with orthogonal techniques (e.g., RNAscope for mRNA)

Given TRAX's role in neurodevelopment and potential implications in neurological disorders, optimizing detection methods for neural tissues is particularly valuable for researchers in neuroscience fields .

How can TRAX antibodies contribute to understanding RNA-mediated gene silencing mechanisms?

Recent discoveries about TRAX's role in activating the RNA-induced silencing complex (RISC) open new research avenues using TRAX antibodies:

• TRAX-RNA interaction studies:

  • RNA immunoprecipitation (RIP) using TRAX antibodies can identify associated RNA species

  • Crosslinking immunoprecipitation (CLIP) methods can map precise RNA binding sites

  • TRAX antibodies can be used in proximity ligation assays to visualize RNA-protein interactions in situ

• Pathway analysis approaches:

  • Immunodepletion of TRAX from cell extracts can assess its requirement in reconstituted silencing assays

  • TRAX antibodies in immunofluorescence can track dynamic localization during siRNA or miRNA-mediated silencing

  • Co-immunoprecipitation can identify novel interaction partners in the silencing machinery

• Quantitative applications:

  • Measure TRAX-TSN complex formation under different cellular conditions

  • Correlate TRAX levels with silencing efficiency across cell types

  • Monitor changes in TRAX localization during development or stress responses

• Methodological considerations:

  • Use RNase inhibitors in all buffers when studying RNA-related functions

  • Consider native (non-denaturing) conditions for preserving functional complexes

  • Include controls to distinguish direct from indirect RNA interactions

This research area has significant implications for understanding fundamental gene regulatory mechanisms and potentially developing RNA-based therapeutics .

What role does TRAX antibody research play in understanding neurodegenerative diseases?

TRAX research has emerging relevance to neurodegenerative diseases through its roles in DNA repair and RNA processing, both of which are implicated in neurodegeneration:

• Disease model applications:

  • Immunohistochemistry with TRAX antibodies can compare expression patterns between normal and neurodegenerative disease tissues

  • Western blot quantification can measure TRAX levels across disease progression

  • Proximity ligation assays can detect altered protein interactions in disease states

• Cellular stress response:

  • TRAX localization changes under oxidative stress can be tracked with immunofluorescence

  • Co-immunoprecipitation can identify stress-specific interaction partners

  • Chromatin association during genotoxic stress can be measured by ChIP

• RNA regulatory dysfunction:

  • Analysis of TRAX-associated RNAs in disease models may reveal dysregulated targets

  • Changes in TRAX post-translational modifications can be detected with modification-specific antibodies

  • Altered TRAX endonuclease activity can be measured in immunoprecipitates from disease samples

• Methodological approaches:

  • Patient-derived iPSCs differentiated to neurons provide disease-relevant human models

  • Animal models of neurodegeneration can be analyzed for TRAX expression and localization changes

  • Brain bank samples enable translational studies with human pathological material

Given TRAX's transcriptional regulation of GAP-43, which is implicated in axonal regeneration, this research direction has potential implications for developing neuroprotective strategies .

What are the most promising techniques for studying TRAX in reproductive biology research?

TRAX has a documented role in spermatogenesis , making reproductive biology an important area for TRAX antibody applications:

• Tissue-specific expression analysis:

  • Immunohistochemistry shows strong cytoplasmic positivity in seminiferous duct cells of human testis

  • Stage-specific expression during spermatogenesis can be mapped using antibodies against TRAX

  • Comparison across species can identify conserved vs. divergent functions

• Subcellular localization studies:

  • High-resolution imaging of TRAX in developing germ cells

  • Co-localization with meiotic machinery components

  • Tracking dynamic changes during spermatogenic differentiation

• Functional approaches:

  • Immunoneutralization experiments in cultured seminiferous tubules

  • Immunoprecipitation followed by mass spectrometry to identify testis-specific interaction partners

  • Correlation of TRAX levels with fertility parameters in model systems

• Technical considerations:

  • For testicular tissue, specialized fixatives like Bouin's solution may provide superior morphology

  • Background reduction is critical due to high endogenous peroxidase activity in reproductive tissues

  • Species-specific optimization may be required due to differences in reproductive biology

• Translational applications:

  • Potential biomarker for male fertility disorders

  • Target for contraceptive development

  • Diagnostic tool for specific forms of infertility

Human testis lysate has been successfully used as a positive control for TRAX antibody validation in multiple studies, confirming its strong expression in reproductive tissues .